A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer

Investigational New Drugs

Volumn 19, Issue 4, 2001, Pages 329-333

  Vokes, Everett E ^a   Gordon, Gary S ^a   Rudin, Charles M ^a   Mauer, Ann M ^a   Watson, Sylvia ^a   Krauss, Stuart ^a   Arrieta, Rose ^a   Golomb, Harvey M ^a   Hoffman, Philip C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

9 Aminocamptothecin; Non small cell lung cancer

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA TOPOISOMERASES, TYPE I; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034875942     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010674113243     Document Type: Article

References (31)

1. Non-small cell lung cancer
2. The camptothecins
3. Topoisomerase I inhibitors: Review and update
4. Phase I and pharmacokinetic trial of weekly CPT-11
5. Phase I and pharmacokinetics study of the camptothecins derivative irinotecan, administered on a weekly schedule in cancer patients
6. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
7. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
8. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
9. A phase I dose-intensification study of irinotecan (CPT-11) with maximized supportive care
10. Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer
11. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511)
12. Phase II study of irinotecan and etoposide in patients with metastatic non-small cell lung cancer
13. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy
14. Phase II study of topotecan in metastatic non-small-cell lung cancer
15. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
16. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-h infusion in adult cancer patients
17. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin
18. Pharmacodynamics and pharmacokinetics of a 72-h infusion of 9-aminocamptothecin in adult cancer patients
19. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer
20. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 h in phase II studies
21. 9-Aminocamptothecin by 72-h continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma
22. Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-h continuous infusion weekly for three weeks in metastatic colorectal carcinoma
23. Phase II trial of 9-aminocamptothecin administered as a 72-h continuous infusion in metastatic colorectal carcinoma
24. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-h continuous infusion weekly times four every 5 weeks
25. Phase II trial of aminocamptothecan (9-AC/DMA) in patients with advanced squamous cell head and neck cancer
26. A phase II study of 9-aminocamptothecin in patients with refractory breast cancer
27. 9-Aminocamptothecin (9AC) (NSC 603071) + GCSF in extensive small cell lung cancer (ESCLC): A phase II California cancer consortium trial
28. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
29. CI-980 in renal cell and non-small cell lung cancer: Multi-institutional trials from the University of Chicago Phase II Consortium